- Home
- BDRX vs CYCC Comparison
BDRX vs CYCC Comparison
Compare BDRX & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- CYCC
- Stock Information
- Founded
- BDRX 2000
- CYCC 1992
- Country
- BDRX United Kingdom
- CYCC United States
- Employees
- BDRX N/A
- CYCC N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- CYCC Health Care
- Exchange
- BDRX Nasdaq
- CYCC Nasdaq
- Market Cap
- BDRX 2.4M
- CYCC 2.3M
- IPO Year
- BDRX N/A
- CYCC N/A
- Fundamental
- Price
- BDRX $3.93
- CYCC $0.34
- Analyst Decision
- BDRX Strong Buy
- CYCC Buy
- Analyst Count
- BDRX 1
- CYCC 2
- Target Price
- BDRX $200.00
- CYCC $11.00
- AVG Volume (30 Days)
- BDRX 381.2K
- CYCC 431.0K
- Earning Date
- BDRX 12-27-2024
- CYCC 11-12-2024
- Dividend Yield
- BDRX N/A
- CYCC N/A
- EPS Growth
- BDRX N/A
- CYCC N/A
- EPS
- BDRX N/A
- CYCC N/A
- Revenue
- BDRX $104,895.00
- CYCC $74,000.00
- Revenue This Year
- BDRX N/A
- CYCC N/A
- Revenue Next Year
- BDRX N/A
- CYCC $88.68
- P/E Ratio
- BDRX N/A
- CYCC N/A
- Revenue Growth
- BDRX N/A
- CYCC N/A
- 52 Week Low
- BDRX $3.50
- CYCC $0.32
- 52 Week High
- BDRX $74.00
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- BDRX 36.40
- CYCC 37.88
- Support Level
- BDRX $4.14
- CYCC $0.33
- Resistance Level
- BDRX $4.39
- CYCC $0.42
- Average True Range (ATR)
- BDRX 0.57
- CYCC 0.04
- MACD
- BDRX -0.06
- CYCC 0.01
- Stochastic Oscillator
- BDRX 3.34
- CYCC 8.21
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.